SAN DIEGO, Nov. 6, 2018 /PRNewswire/ -- MEI Pharma,
Inc. (Nasdaq: MEIP), a late-stage pharmaceutical company focused on
advancing new therapies for cancer, today announced that
Daniel P. Gold, Ph.D., the Company's
president and chief executive officer, will present a corporate
update at the Stifel 2018 Healthcare Conference on November 13, 2018 at 9:30
a.m. ET. The conference will take place November 13-14, in New
York, N.Y.
A live audio webcast of the event can be accessed on the Events
& Presentations page of the Investors section of MEI Pharma's
website at http://www.meipharma.com.
An archived replay of the webcast will be available on MEI
Pharma's website for at least 30 days after the live event
concludes.
About MEI Pharma
MEI Pharma, Inc. (Nasdaq: MEIP) is
a San Diego-based pharmaceutical company focused on leveraging
its extensive development and oncology expertise to identify and
advance new therapies for cancer. The Company's portfolio of drug
candidates includes pracinostat, an oral HDAC inhibitor that is
partnered with Helsinn Healthcare, SA. Pracinostat has been granted
Breakthrough Therapy Designation from the U.S. Food and Drug
Administration for use in combination with azacitidine for the
treatment of patients with newly diagnosed acute myeloid leukemia
(AML) who are unfit for intensive chemotherapy. Pracinostat is also
being developed in combination with azacitidine for the treatment
of patients with high and very high-risk myelodysplastic syndrome
(MDS). MEI Pharma's clinical development pipeline also includes
ME-401, a highly differentiated oral PI3K delta inhibitor currently
in a Phase 1b study in patients with relapsed refractory
follicular lymphoma or CLL, and voruciclib, an oral, selective CDK
inhibitor shown to suppress MCL1, a known mechanism of resistance
to BCL2 inhibitors. The Company is also developing ME-344, a novel
mitochondrial inhibitor currently in an investigator-initiated
study in combination with bevacizumab evaluating patients with
HER2-negative breast cancer. Pracinostat, ME-401, ME-344 and
voruciclib are investigational agents and are not approved for use
in the U.S. For more information, please
visit www.meipharma.com.
Under U.S. law, a new drug cannot be marketed until it has
been investigated in clinical studies and approved by the FDA as
being safe and effective for the intended use. Statements included
in this press release that are not historical in nature are
"forward-looking statements" within the meaning of the "safe
harbor" provisions of the Private Securities Litigation Reform Act
of 1995. You should be aware that our actual results could differ
materially from those contained in the forward-looking statements,
which are based on management's current expectations and are
subject to a number of risks and uncertainties, including, but not
limited to, our failure to successfully commercialize our product
candidates; costs and delays in the development and/or FDA
approval, or the failure to obtain such approval, of our product
candidates; uncertainties or differences in interpretation in
clinical trial results; our inability to maintain or enter into,
and the risks resulting from our dependence upon, collaboration or
contractual arrangements necessary for the development,
manufacture, commercialization, marketing, sales and distribution
of any products; competitive factors; our inability to protect our
patents or proprietary rights and obtain necessary rights to third
party patents and intellectual property to operate our business;
our inability to operate our business without infringing the
patents and proprietary rights of others; general economic
conditions; the failure of any products to gain market acceptance;
our inability to obtain any additional required financing;
technological changes; government regulation; changes in industry
practice; and one-time events. We do not intend to update any of
these factors or to publicly announce the results of any revisions
to these forward-looking statements.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/mei-pharma-to-present-at-stifel-2018-healthcare-conference-300744425.html
SOURCE MEI Pharma, Inc.